@Article{or.2026.077158,
AUTHOR = {Giovanni Leuzzi, Michele Ferrari, Federica Sabia, Alessandro Pardolesi, Alessia Stanzi, Claudia Proto, Giuseppe Lo Russo, Arsela Prelaj, Monica Ganzinelli, Matteo Calderoni, Clarissa Uslenghi, Ugo Pastorino, Piergiorgio Solli},
TITLE = {Induction Therapy Followed by Surgery in Advanced Thymic Epithelial Tumors: A 20-Year Systematic Review and Meta-Analysis},
JOURNAL = {Oncology Research},
VOLUME = {},
YEAR = {},
NUMBER = {},
PAGES = {{pages}},
URL = {http://www.techscience.com/or/online/detail/27292},
ISSN = {1555-3906},
ABSTRACT = {<b>Backgrounds:</b> Despite the availability of multimodal strategies, no universally accepted guidelines exist for the management of advanced Thymic Epithelial Tumors (TETs), particularly in locally advanced thymomas. The aim of this study was to evaluate the oncological and surgical outcomes of induction therapy (IT) followed by surgery in patients with Masaoka–Koga stage III–IVA TETs. To this end, we conducted a systematic review and meta-analysis assessing surgical-pathological and survival outcomes. <b>Methods:</b> Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was performed. Twenty-four studies published between 2003 and 2023 were included, comprising 749 patients treated with IT before surgical resection. The co-primary endpoints were Overall survival (OS) and Progression-free survival (PFS). Random-effects meta-analysis assessed pooled outcomes, while heterogeneity, publication bias, and meta-regression analyses were performed to explore potential moderators (year, histology, stage). The study was registered in Prospective Register of Systematic Reviews (PROSPERO) (CRD420251026044). <b>Results:</b> Of the included studies, 6 were prospective and 18 retrospective; 9 analyzed thymomas only, while 15 included both thymomas and thymic carcinomas. Regarding stage distribution, 4 studies focused on stage III, 11 on stage III–IV, 3 on stage IV, and 2 also included earlier stages. Response to IT was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) in 11 studies and World Health Organization (WHO) criteria in 4. The pooled rate of radiological response to IT, completeness of resection, 5-year OS, 10-year OS and 5-year PFS were 62.8%, 71.6%, 77.6%, 54.3% and 55.6%, respectively. Meta-regression showed histology significantly influenced 10-year OS (<i>p</i>-value 0.0418) as well as on PFS (<i>p</i>-value 0.0042) and treatment period on PFS (<i>p</i>-value 0.0007) <b>Conclusions:</b> Induction therapy followed by surgery provides acceptable long-term outcomes in advanced TETs. Histology remains a key prognostic factor, but 10-year OS has not improved over the past two decades, underscoring the need for innovative, histology-tailored therapeutic strategies to enhance survival.},
DOI = {10.32604/or.2026.077158}
}